开源证券给予通策医疗买入评级：2025上半年业绩稳健增长，正畸业务企稳回升

Group 1 - The core viewpoint of the report is that Tongce Medical (600763.SH) is rated as a "buy" due to expected stable growth in performance and improved profitability in the first half of 2025 [1] - The orthodontics business is showing signs of recovery, with the number of dental chairs exceeding 3,100 [1] - The company is implementing a "three-three system" model to drive development, although the business of the three major hospitals has seen a decline [1]